|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Affitech AS, of Oslo, Norway, said it unveiled a new screening process for the direct isolation of human antibodies from diseased tissue. By eliminating preselection, the process ensures the antibodies are chosen primarily for their binding characteristics, Affitech said. The technology was presented at a conference on antibodies in Berlin.
Amarin Corp. plc said its subsidiary in Malmo, Sweden, Amarin Development AB, entered an partnership with Eiffel Research and Development Pty. Ltd., of Melbourne, Australia, to develop extended-release drugs by combining Amarin's technologies with Eiffel's supercritical fluid engineering technologies.
Amgen Inc., of ...